The companies have introduced Actiste, the first complete IoT-health solution for monitoring and treating insulin-dependent diabetes.
Ericsson and Swedish health technology company Brighter have teamed up to create a new treatment for diabetes: Actiste. It’s the first IoT-based solution designed to monitor and treat insulin-dependent diabetes. currently available in the UAE where 1.2 million people live with diabetes, the companies hope to make it available worldwide.
Henrik Norström, Brighter AB CEO says: “By partnering with Ericsson, we are able to offer a truly seamless customer experience. No matter where in the world patients decide to go, their generated health and treatment data will always be securely stored and available to improve their treatments.”
See also: Why the Radiology Community is Eager to Embrace AI
Actiste combines blood sampling, glucose level measurement, and insulin injection into a single device. The partners have not yet announced pricing for this subscription service. The service will include:
- Data sharing
- Supply replenishment
- Global connectivity
- Individualized coaching
Cellular-enabled and managed by Ericsson’s IoT Accelerator, a variety of leading communications service providers will support it. The product boasts out-of-the-box connectivity with eSIM and patented technology that collects data on specified bio-markers and volume of medication.
Fadi Pharaon, President of Ericsson Middle East and Africa, says: “This is an important milestone for how connectivity can transform people’s lives for the better. Our global partnership with Brighter has now reached a stage of real deliveries to the market, utilizing the global connectivity service based on our IoT Accelerator. The result is an enhanced healthcare industry in the UAE and wider GCC, and an improved quality of life for diabetes patients.”
